

**A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype**

Birgitte G. Tougaard<sup>1</sup>, Katja Venborg Pedersen<sup>3</sup>, Søren Rasmus Palmelund Krag<sup>2</sup>, Janet A. Gilbertson<sup>4</sup>, Dorota Rowczenio<sup>4</sup>, Julian D. Gillmore<sup>4</sup>, Henrik Birn<sup>1</sup>,

**<sup>1</sup>Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark; <sup>2</sup>Department of Pathology, Aarhus University Hospital, Aarhus, Denmark; <sup>3</sup>Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark; <sup>4</sup>National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, London, United Kingdom.**

Key Words: Variable phenotype, Hereditary, Amyloidosis, Apolipoprotein A-I encoding mutation, APOA1.

*Correspondence to:*

Birgitte G. Tougaard, MD

Department of Renal Medicine

Aarhus University Hospital

Brendstrupsgaardsvej 100

DK-8200 Aarhus N, Denmark

E-mail: bgtougaard@gmail.com

## **Abstract**

Apolipoprotein A-I (apoAI) amyloidosis is a non-AL, non-AA, and non-transthyretin type of amyloidosis associated with mutations in the *APOA1* gene inherited in an autosomal dominant fashion. It is a form of systemic amyloidosis, but at presentation, can also mimic localized amyloidosis. The renal presentation generally involves interstitial and medullary deposition of apo A-I amyloid protein. We describe the identification of apo A-I amyloidosis by mass spectrometry in a 52-year old male, with no family history of amyloidosis, presenting with nephrotic syndrome and associated with heterozygosity for a novel *APOA1* mutation (c.220T>A) which encodes the known amyloidogenic Trp50Arg variant. Renal amyloid deposits in this case were confined to the glomeruli alone, and the patient developed progressive renal impairment. One year after diagnosis, the patient had a successful kidney transplant from an unrelated donor. Pathogenic mutation in the *APOA1* gene are generally associated with symptoms of amyloidosis. In this family however, genotyping of family members identified several unaffected carriers suggesting a variable disease penetrance, which has not been described before in this form of amyloidosis and has implications when counselling those with *APOA1* mutations.

## **Introduction:**

Amyloidosis is characterized by extracellular deposition of insoluble protein and peptides. Accumulation of amyloid in tissues, as well as oligomers of amyloid protein may cause organ damage, and if affecting the kidney, is often associated with progression to end stage renal disease. [Bergesio F, et al. 2008]

Hereditary amyloidosis is caused by mutations in specific, protein encoding genes leading to misfolding and aggregation of the protein. Several proteins have been identified including fibrinogen A- $\alpha$  chain [Benson MD, 2003], transthyretin [Ando Y, et al. 2013], apolipoprotein A-I (apo A-I) [Obici L, et al. 2006], apolipoprotein A-II (apo-AII) [Yazaki M, et al, 2001], lysosome [DR Booth et. al 1969] and gelsolin. [Benson MD, 2003]

Mutations in the *APOA1* gene are associated with autosomal dominant inherited amyloidosis [Van Allen MW, Frohlich JA, Davis JR, 1969]. To date, 20 different amyloidogenic mutations in *APOA1* are listed in the Human Genome Database (HGMD: <http://www.hgmd.cf.ac.uk/ac/index.php>; accessed on June 2015). The majority of these are missense/nonsense mutations but small deletions/insertions have also been reported. The *APOA1* gene mutations are associated with systemic amyloidosis, but can initially present as localized disease, particularly in the larynx and skin. Multiple organs including liver, kidneys, peripheral nerves, gastrointestinal tract, testes, spleen, heart, larynx, and skin may be involved. The clinical presentation varies from severe and progressive cardiac failure at the age of 20 and death in the late 4<sup>th</sup> decade, to late onset disease presenting in the 5<sup>th</sup> decade with gradually progressing renal failure. Renal involvement is common and most often characterized by amyloid deposition in the medullary interstitium and/or vasculature. In most cases of apoAI amyloidosis caused by *APOA1* mutations,

there is a prior family history of similar disease (Table I) and so far, unaffected mutation carriers have not been described. [Erikson M et al, 2000]

### **Results:**

A 52-year old Danish male with no family history of renal disease presented with hypertension, renal insufficiency, and nephrotic syndrome. At presentation, he had an eGFR of 36 ml/min/1.73m<sup>2</sup> and proteinuria in the range of ~7 g/24 h. A kidney biopsy revealed amyloid with extensive glomerular involvement (Figure 1). Immunostaining for serum amyloid A protein (SAA), kappa and lambda immunoglobulin light chains and transthyretin were all negative. A bone marrow aspirate and trephine biopsy were normal without clonal plasma cells or amyloid. Nerve conduction studies were normal and cardiac investigations, including echocardiography and cardiac biomarkers did not suggest cardiac infiltration by amyloid. Proteomic analysis of microdissected amyloid deposits from a kidney biopsy revealed large amounts of apoAI, which scored as number one, in conjunction with the amyloid ‘signature’ proteins serum amyloid P component and apolipoprotein E (figure 1D). Simultaneously, specific staining of glomeruli with antibodies against apoAI (figure 1B) also confirmed the presence of apoAI protein. Subsequent sequencing of *APOA1* revealed heterozygosity for a mutation encoding the Trp50Arg variant, c.220T>A (cDNA reference sequence NM\_000039.1). No mutations in other amyloid genes were identified. Except for paresthesia, there were no symptoms of extra-renal involvement by amyloid. Serum amyloid P component (SAP) scintigraphy revealed a large total body amyloid load with deposits in the liver, spleen, and kidneys (figure 1C). Despite treatment, including an angiotensin II receptor blocker and a statin, significant albuminuria persisted and kidney function declined to end-stage kidney disease within 10 months of diagnosis. Genetic analysis of the patient’s family identified the mother, two older brothers, and a

younger sister as mutation carriers but with no symptoms or signs of amyloidosis. The proband received a successful unrelated kidney transplant approximately 6 months later.

### **Discussion:**

ApoAI amyloidosis in this case was suggested by immunohistochemistry and confirmed by mass spectrometry [Sethi S. et al. 2013] and genetic analysis. An extensive work up showed no signs of monoclonal disease or inflammatory disease, supporting the pathogenicity of the glomerular apoAI amyloid deposits presenting with nephrotic syndrome and leading to end stage renal failure. In general, renal involvement in apoA1 amyloidosis is believed to be medullary/interstitial rather than glomerular. In this case, however, the amyloid deposits were identified only in the glomeruli reported only in three other cases. (Table I)

A single case of an identical amino acid substitution due to a different, single nucleotide exchange (APOA1 c.220T>C) has previously been reported in a patient with a family history of amyloidosis. [Booth DR, et al. 1995]. The patient presented with symptoms of amyloidosis at age 35 years and had widespread organ involvement, including liver, spleen, and gastrointestinal tract. Renal involvement was noted in a kidney biopsy; however, kidney function only slowly declined leading to a kidney transplantation 10 years after presentation. In the current case, a culprit *APOA1* mutation was identified in several family members with no signs or symptoms of amyloidosis, including the patient's mother at 80-years of age. Thus, the mutation and resulting amino acid substitution is associated with interfamilial and intrafamilial variability in disease penetrance. It is not known whether this may be due to variable expression of the variant. The recognition of this variation in disease penetrance is important for the counselling of clinically unaffected family members with a similar genotype.

In conclusion, the current case demonstrates the successful identification of apoAI amyloidosis by proteomic analysis of amyloid deposits associated with a novel *APOA1* mutation encoding a previously reported pathogenic apoAI variant. Genotyping of family members identified several unaffected older carriers indicating variable penetrance. The patient presented with nephrotic syndrome, which is unusual in this form of amyloidosis, and the renal biopsy showed isolated glomerular amyloid deposits that may mimic other types of amyloidosis.

**Acknowledgement:**

There has been no financial support in the process of making this report. The Institute of Laboratory Medicine and Human Genetics, Singen, Germany performed the analyses of the APOA1 gene.

## References:

Amarzguioui M, Mucchiano G, Haggqvist B, et al. Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. *Biochem.Biophys.Res.Comm.* 1998; 242: 534-539.

Benson MD. The hereditary amyloidosis. *Best Pract.Res.Clin.Rheumatol.* 2003; 17: 909-927

Booth DR, Tan SY, Booth SE, et al. A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. *QJM* 1995; 88: 695-702.25.

Booth DR, Tan SY, Booth SE, et al. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. *J.Clin.Invest.* 1996; 97: 2714-2721.

Caballeria J, Bruguera M, Sole M, Campistol JM, Rodes J. Hepatic familial amyloidosis caused by a new mutation in the apolipoprotein AI gene: clinical and pathological features. *Am.J.Gastroenterol.* 2001; 96: 1872-1876.

Coriu D, Dispenzieri A, Stevens FJ, et al. Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro. *Amyloid* 2003; 10: 215-223.

Eriksson M, Schonland S, Yumlu S, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. *J.Mol.Diagn.* 2009; 11: 257-262.

Gregorini G, Izzi C, Obici L, et al. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. *J.Am.Soc.Nephrol.* 2005; 16: 3680-3686.

Gillmore JD, Lachmann HJ, Rowczenio D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. *J.Am.Soc.Nephrol.* 2009; 20: 444-451.

Gina Gregorini,\* Claudia Izzi,\* Laura Obici,† Regina Tardanico,‡ Christoph Röcken,§ Battista Fabio Viola,\* Mariano Capistrano,\* Simona Donadei,† Luciano Biasi,. Renal Apolipoprotein A-I Amyloidosis: A Rare and Usually Ignored Cause of Hereditary Tubulointerstitial Nephritis. *J.Am. Soc. Nephrol.* 16, 3680-3686

Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis.

*Biochem.Biophys.Res.Commun.* 1999; 257: 584-588.

Hazenberg AJ, Dikkers FG, Hawkins PN, et al. Laryngeal presentation of systemic apolipoprotein A-I-derived amyloidosis. *Laryngoscope* 2009; 119: 608-615.

Mollee P, Renaut P, Gottlieb D, Goodman H. How to diagnose amyloidosis. *Intern.Med.J.* 2013;

Murphy CL, Wang S, Weaver K, Gertz MA, Weiss DT, Solomon A. Renal apolipoprotein A-I amyloidosis associated with a novel mutant Leu64Pro. *Am.J.Kidney Dis.* 2004; 44: 1103-1109.

Nichols WC, Dwulet FE, Liepnieks J, Benson MD. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. *Biochem.Biophys.Res.Commun.* 1988; 156: 762-768.

Nichols WC, Gregg RE, Brewer HB, Jr, Benson MD. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. *Genomics* 1990; 8: 318-323

Obici L, Bellotti V, Mangione P, et al. The new apolipoprotein A-I variant leu (174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. *Am.J.Pathol.* 1999; 155: 695-702.

Persey MR, Booth DR, Booth SE, et al. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. *Kidney Int.* 1998; 53: 276-281.

Rowczenio D, Dogan A, Theis JD, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. *Am.J.Pathol.* 2011; 179: 1978-1987.

Sethi S, Vrana JA, This JD, Dogan A. Mass spectrometry based proteomics in the diagnosis of kidney disease. *Curr. Opin. Nephrol. Hypertens.* 2013:

Soutar AK, Hawkins PN, Vigushin DM, et al. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. *Proc.Natl.Acad.Sci.U.S.A.* 1992; 89: 7389-7393.

Van Allen MW, Frohlich JA, Davis JR. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. *Neurology* 1969; 19: 10-25.

Vigushin DM, Gough J, Allan D, et al. Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. *Q.J.Med.* 1994; 87: 149-154.

Yazaki M, Liepnieks JJ, Yamashita T, Guenther B, Skinner M, Benson MD. Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene. *Kidney Int.* 2001; 60: 1658-1665.